Search

Your search keyword '"Orvieto, E."' showing total 142 results
Start Over Author "Orvieto, E."
142 results on '"Orvieto, E."'

2. Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer

Author

Dieci, M.V., Conte, P., Bisagni, G., Brandes, A.A., Frassoldati, A., Cavanna, L., Musolino, A., Giotta, F., Rimanti, A., Garrone, O., Bertone, E., Cagossi, K., Sarti, S., Ferro, A., Piacentini, F., Maiorana, A., Orvieto, E., Sanders, M., Miglietta, F., Balduzzi, S., D’Amico, R., and Guarneri, V.

Published
2019
Full Text
View/download PDF

6. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

Author

El Bairi, K., Haynes, H. R., Blackley, E., Fineberg, S., Shear, J., Turner, S., de Freitas, J. R., Sur, D., Amendola, L. C., Gharib, M., Kallala, A., Arun, I., Azmoudeh-Ardalan, F., Fujimoto, L., Sua, L. F., Liu, S. -W., Lien, H. -C., Kirtani, P., Balancin, M., El Attar, H., Guleria, P., Yang, W., Shash, E., Chen, I. -C., Bautista, V., Do Prado Moura, J. F., Rapoport, B. L., Castaneda, C., Spengler, E., Acosta-Haab, G., Frahm, I., Sanchez, J., Castillo, M., Bouchmaa, N., Md Zin, R. R., Shui, R., Onyuma, T., Husain, Z., Willard-Gallo, K., Coosemans, A., Perez, E. A., Provenzano, E., Ericsson, P. G., Richardet, E., Mehrotra, R., Sarancone, S., Ehinger, A., Rimm, D. L., Bartlett, J. M. S., Viale, G., Denkert, C., Hida, A. I., Sotiriou, C., Loibl, S., Hewitt, S. M., Badve, S., Symmans, W. F., Kim, R. S., Pruneri, G., Goel, S., Francis, P. A., Inurrigarro, G., Yamaguchi, R., Garcia-Rivello, H., Horlings, H., Afqir, S., Salgado, R., Adams, S., Kok, M., Dieci, M. V., Michiels, S., Demaria, S., Loi, S., Schelfhout, V., Arbzadeh, E., Bondanar, A., Reyes, S. A. G., Ruz, J. R., Kang, J., Xiang, L., Zimovjanova, M., Togores, P., Ozturk, T., Patil, A., Corpa, M., Whitehouse, A., Tan, B., de Paula, A., Rossetti, C., Lang-Schwarz, C., Mahon, S., Giacometti, C., Linderholm, B., Deman, F., Montagna, G., Gong, G., Pavcovich, M., Chaer, Y., Cabrero, I. A., de Brito, M. L., Ilieva, N., Fulop, A., Souza, M., Bilancia, D., Idowu, M., Johri, R., Szpor, J., Bachani, L., Schmitt, F., Giannotti, M., Kurebayashi, Y., Ramirez, B. E. A., Salido, E., Bortesi, L., Bonetto, S., Elomina, K., Lopez, P., Sharma, V., Edirisinghe, A., Mathur, D., Sahay, A., Mouloud, M. A., Giang, C. H., Mukolwe, E., Kiruka, E., Samberg, N., Abe, N., Brown, M., Millar, E., X. B., Li, Yuan, Z., Pasupathy, A., Miele, R., Luff, R., e Porfirio, M. M. A., Ajemba, O., Soni, R., Orvieto, E., Dimaio, M., Thomas, J., Merard, R., Subramaniam, M. M., Apolinario, T., Preda, O., Preda, R., Makanga, A., Maior, M. S., Li, L., Saghatchian, M., Saurine, T., Janssen, E., Cochran, J., Vlada, N., Cappellesso, R., Elfer, K., Hollick, M., Desai, S., Oner, G., Schreurs, A., Liu, S., Perera, R., Mercurio, P., Garcia, F., Hosny, K., Matsumoto, H., van Deurzen, C., Bianchini, G., Coban, I., Jahangir, A., Rahman, A., Stover, D., Luz, P., Martel, A., Waumans, Y., Stenzinger, A., Cortes, J., Dimitrova, P., Nauwelaers, I., Velasco, M., Fan, F., Akturk, G., Firer, M., Roxanis, I., Schneck, M., Wen, H., Cockenpot, V., Konstantinov, A., Calatrava, A., Vidya, M. N., Choi, H. J., Jank, P., Ciinen, A. H., Sabanathan, D., Floris, G., Hoeflmayer, D., Hamada, T., Laudus, N., Grigoriadis, A., Porcellato, I., Acs, B., Miglietta, F., Parrodi, J., Clunie, D., Calhoun, B., F. -I., Lu, Lefevre, A., Tabbarah, S., Tran, W., Garcia-murillas, I., Jelinic, P., Boeckx, C., Souza, S., Cebollero, M. C., Felip, E., Rendon, J. L. S., El Gabry, E., Saltz, J., Bria, E., Garufi, G., Hartman, J., Sebastian, M., Olofsson, H., Kooreman, L., Cucherousset, J., Mathieu, M. -C., Ballesteros-Merino, C., Siziopikou, P., Fong, J., Klein, M., Qulis, I. R. I., Wesseling, J., Bellolio, E., Araya, J. C., Naber, S., Cheang, M., Castellano, I., Ales, A., Laenkholm, A. -V., Kulka, J., Quinn, C., Sapino, A., Amendoeira, I., Marchio, C., Braybrooke, J., Vincent-Salomon, A., Korski, K. P., Sofopoulos, M., Stovgaard, E. I. S., Bianchi, S., Bago-Horvath, Z., Yu, C., Regitnig, P., Hall, S., Kos, Z., Sant, S., Tille, J. -C., Gallas, B., Bethmann, D., Savas, P., Mendes, L., Soler, T., van Seijen, M., Gruosso, T., Quintana, A., Giltnane, J., Van den Eynden, G., Duregon, E., de Cabo, R., Recamo, P. C., Gaboury, L., Zimmerman, J., Pop, C. S., Wernicke, A., Williams, D., Gill, A., Solomon, B., Thapa, B., Farshid, G., Gilham, L., Christie, M., O'Toole, S., Hendry, S., Fox, S. B., Luen, S. J., Lakhani, S. R., Fuchs, T., John, T., Brcic, I., Hainfellner, J., Sigurd, L., Preusser, M., Poortmans, P., Decaluwe, A., Carey, C., Colpaert, C., Larsimont, D., Peeters, D., Broeckx, G., van de Vijver, K., Buisseret, L., Dirix, L., Hertoghs, M., Piccart, M., Ignatiadis, M., Van Bockstal, M., Sirtaine, N., Vermeulen, P., de Wind, R., Declercq, S., Gevaert, T., Haibe-Kans, B., Nelson, B. H., Watson, P. H., Leung, S., Nielsen, T., Shi, L., Balslev, E., Thagaard, J., Almangush, A., Makitie, A., Joensuu, H., Lundin, J., Drubay, D., Roblin, E., Andre, F., Penault-Llorca, F., Lemonnier, J., Adam, J., Lacroix-Triki, M., Ternes, N., Radosevic-Robin, N., Klaushen, F., Weber, K., Harbeck, N., Gluz, O., Wienert, S., Cserni, G., Vingiani, A., Criscitiello, C., Solinas, C., Curigliano, G., Konishi, E., Suzuki, E., Yoshikawa, K., Kawaguchi, K., Takada, M., Toi, M., Ishida, M., Shibata, N., Saji, S., Kogawa, T., Sakatani, T., Okamoto, T., Moriya, T., Kataoka, T., Shimoi, T., Sugie, T., Mukohara, T., Shu, Y., Kikawa, Y., Kozuka, Y., Sayed, S., Rahayu, R., Ramsaroop, R., Senkus-Konefka, E., Chmielik, E., Cardoso, F., Ribeiro, J., Chan, J., Dent, R., Martin, M., Hagen, C., Guerrero, A., Rojo, F., Comerma, L., Nuciforo, P., Serrano, V. V., Camaea, V. P., Steenbruggen, T., Ciompi, F., Nederlof, I., Jan, Hudecek, van der Laak, J., van den Berg, J., Voorwerk, L., van de Vijver, M., de Maaker, M., Linn, S., Mckenzie, H., Somaiah, N., Tutt, A., Swanton, C., Hiley, C., Moore, D. A., Hall, J. A., Le Quesne, J., Jabbar, K. A., al Bakir, M., Hills, R., Irshad, S., Yuan, Y., Li, Z., Liu, M., Klein, J., Fadare, O., Thompson, A., Lazar, A. J., Gown, A., Lo, A., Garrido Castro, A. C., Madabhushi, A., Moreira, A., Richardson, A., Beck, A. H., Bellizzi, A. M., Wolff, A., Harbhajanka, A., Sharma, A., Cimino-Mathews, A., Srinivasan, A., Singh, B., Chennubhotla, C. S., Chauhan, C., Dillon, D. A., Zardavas, D., Johnson, D. B., Thompson, A. E., Brogi, E., Reisenbichler, E., Huang, E., Hirsch, F. R., Mcarthur, H., Ziai, J., Brock, J., Kerner, J., Zha, J., Lennerz, J. K., Carter, J. M., Reis-Filho, J., Sparano, J., Balko, J. M., Pogue-Geile, K., Steele, K. E., Blenman, K. R. M., Allison, K. H., Pusztai, L., Cooper, L., Estrada, V. M., Flowers, M., Robson, M., Rebelatto, M. C., Hanna, M. G., Goetz, M. P., Khojasteh, M., Sanders, M. E., Regan, M. M., Misialek, M., Amgad, M., Tung, N., Singh, R., Huang, R., Pierce, R. H., Leon-Ferre, R., Swain, S., Ely, S., Kim, S. -R., Bedri, S., Paik, S., Schnitt, S., D'Alfons, T., Kurkure, U., Bossuyt, V., Tong, W., Wang, Y., Dos Anjos, C. H., Gaire, F., Van Diest, P. J., El Bairi, Khalid [0000-0002-8414-4145], de Freitas, Juliana Ribeiro [0000-0003-4978-7273], Sur, Daniel [0000-0002-0926-4614], Amendola, Luis Claudio [0000-0002-6404-450X], Azmoudeh-Ardalan, Farid [0000-0003-4701-0532], Kirtani, Pawan [0000-0002-2343-7016], Yang, Wenxian [0000-0002-5349-9680], Castillo, Miluska [0000-0002-0111-3176], Provenzano, Elena [0000-0003-3345-3965], Mehrotra, Ravi [0000-0001-9453-1408], Ehinger, Anna [0000-0001-9225-7396], Rimm, David L [0000-0001-5820-4397], Bartlett, John MS [0000-0002-0347-3888], Denkert, Carsten [0000-0002-2249-0982], Hida, Akira I [0000-0002-4486-8819], Sotiriou, Christos [0000-0002-5745-9977], Hewitt, Stephen M [0000-0001-8283-1788], Badve, Sunil [0000-0001-8861-9980], Symmans, William Fraser [0000-0002-1526-184X], Goel, Shom [0000-0001-8329-9084], Francis, Prudence A [0000-0002-7207-9286], Horlings, Hugo [0000-0003-4782-8828], Salgado, Roberto [0000-0002-1110-3801], Demaria, Sandra [0000-0003-4426-0499], Loi, Sherene [0000-0001-6137-9171], Apollo - University of Cambridge Repository, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'anatomie pathologique, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), and UNICANCER

Subjects
Oncology, medicine.medical_treatment, [SDV]Life Sciences [q-bio], TRASTUZUMAB, Improved survival, MICROENVIRONMENT, Review Article, SUBTYPES, NEOADJUVANT CHEMOTHERAPY, 0302 clinical medicine, Breast cancer, Ecology,Evolution & Ethology, PROGNOSTIC-SIGNIFICANCE, Medicine and Health Sciences, Pharmacology (medical), TUMOR-INFILTRATING LYMPHOCYTES, Stage (cooking), RC254-282, Chemical Biology & High Throughput, 0303 health sciences, Human Biology & Physiology, Genome Integrity & Repair, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, ASSOCIATION, 3. Good health, 030220 oncology & carcinogenesis, Biomarker (medicine), Life Sciences & Biomedicine, Genetics & Genomics, medicine.medical_specialty, chemical and pharmacologic phenomena, International Immuno-Oncology Biomarker Working Group, Predictive markers, 03 medical and health sciences, Signalling & Oncogenes, SDG 3 - Good Health and Well-being, Internal medicine, 692/53/2423, medicine, Radiology, Nuclear Medicine and imaging, In patient, 030304 developmental biology, Computational & Systems Biology, Science & Technology, IDENTIFICATION, business.industry, review-article, Cancer, 03.01. Általános orvostudomány, Immunotherapy, Tumour Biology, medicine.disease, PREDICTIVE-VALUE, 692/4028/67/1347, Programmed death 1, business, FREE SURVIVAL
Abstract

The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC. ispartof: NPJ BREAST CANCER vol:7 issue:1 ispartof: location:United States status: published

Published
2021
Full Text
View/download PDF

8. 19P PIK3CA mutations in HER2-positive early breast cancer patients enrolled in the adjuvant randomized short-HER study

Author

Guarneri, V., primary, Dieci, M.V., additional, Bisagni, G., additional, Brandes, A.A., additional, Frassoldati, A., additional, Cavanna, L., additional, Musolino, A., additional, Giotta, F., additional, Rimanti, A., additional, Garrone, O., additional, Bertone, E., additional, Cagossi, K., additional, Nanni, O., additional, Piacentini, F., additional, Orvieto, E., additional, Curtarello, M., additional, Chic, N., additional, D'Amico, R., additional, Prat, A., additional, and Conte, P.F., additional

Published
2020
Full Text
View/download PDF

9. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study

Author

Dieci, M. V., Guarneri, V., Zustovich, F., Mion, M., Morandi, P., Bria, Emilio, Merlini, L., Bullian, P., Oliani, C., Gori, S., Giarratano, T., Orvieto, E., Griguolo, G., Michieletto, S., Saibene, T., Del Bianco, P., De Salvo, G. L., Conte, Pietro, Bria E. (ORCID:0000-0002-2333-704X), Dieci, M. V., Guarneri, V., Zustovich, F., Mion, M., Morandi, P., Bria, Emilio, Merlini, L., Bullian, P., Oliani, C., Gori, S., Giarratano, T., Orvieto, E., Griguolo, G., Michieletto, S., Saibene, T., Del Bianco, P., De Salvo, G. L., Conte, Pietro, and Bria E. (ORCID:0000-0002-2333-704X)

Abstract

Background: The ROXANE Italian prospective study evaluated the impact of the 21-gene Recurrence Score (RS) results on adjuvant treatment decision for patients with early breast cancer. Materials and Methods: Nine centers participated. Physicians used the RS test whenever unsure about adjuvant treatment recommendation for patients with estrogen receptor-positive/human epidermal growth receptor 2-negative, T1–T3, N0–N1 early breast cancer. Pre-RS and post-RS treatment recommendations were collected. Results: A total of 251 patients were included. N0 patients (61%) showed higher grade (p <.001) and higher Ki67 (p =.001) and were more frequently progesterone receptor negative (p =.012) as compared with N1 patients. RS results were as follows: <11, n = 63 (25.1%); 11–25, n = 143 (57%); and ≥26, n = 45 (17.9%). Higher RS was found in N0 vs. N1 patients (p =.001) and in cases of G3 (p <.001) and higher Ki67 (p <.001). The rate of change in treatment decision was 30% (n = 75), mostly from chemotherapy (CT) plus hormone therapy (CT + HT) to hormone therapy (HT; 76%, n = 57/75). The proportion of patients recommended to CT + HT was significantly reduced from pre-RS to post-RS (52% to 36%, p <.0001). CT use reduction was more evident for N1 patients (55% to 27%) than for N0 patients (50% to 42%) and was observed only in cases of RS ≤17. Conclusion: Physicians predominantly used the 21-gene assay in N0 patients with a more aggressive biology or in N1 patients showing more indolent biology. In this selected patient population, the use of RS testing led to a 30% rate of change in treatment decision. In the N1 patient subgroup, the use of RS testing contributed to reduce CT use by more than half. Implications for Practice: This study shows that, even in a context in which physicians recommend a high proportion of patients to endocrine treatment alone before knowing the results of the Recurrence Score (RS) assay, the use of the RS test, whenever uncertainty regarding

Published
2019

10. Abstract P4-08-04: PD-L1 expression and prognosis in triple negative breast cancer (TNBC): An analysis of 265 patients (pts) treated with standard therapy for stage I-III disease

Author

Dieci, MV, primary, Orvieto, E, additional, Tsvetkova, V, additional, Griguolo, G, additional, Miglietta, F, additional, Bonaguro, S, additional, Tasca, G, additional, Giorgi, CA, additional, Cumerlato, E, additional, Guarneri, V, additional, and Conte, P, additional

Published
2019
Full Text
View/download PDF

13. A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure invasive lobular breast carcinoma (ILC)

Author

Carbognin, L., primary, Sperduti, I., additional, Arpino, G., additional, Dieci, M.V., additional, Schettini, F., additional, Griguolo, G., additional, Brunelli, M., additional, Guarneri, V., additional, Nortilli, R., additional, Fiorio, E., additional, Pilotto, S., additional, Orvieto, E., additional, Manfrin, E., additional, Conte, P., additional, de Placido, S., additional, Scambia, G., additional, Tortora, G., additional, and Bria, E., additional

Published
2018
Full Text
View/download PDF

14. Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial

Author

Dieci, M.V., primary, Conte, P.F., additional, Bisagni, G., additional, Brandes, A.A., additional, Frassoldati, A., additional, Cavanna, L., additional, Musolino, A., additional, Giotta, F., additional, Rimanti, A., additional, Garrone, O., additional, Bertone, E., additional, Cagossi, K., additional, Sarti, S., additional, Ferro, A., additional, Omarini, C., additional, Maiorana, A., additional, Orvieto, E., additional, Sanders, M., additional, D'Amico, R., additional, and Guarneri, V., additional

Published
2018
Full Text
View/download PDF

15. Abstract P1-13-02: Withdrawn

Author

Guarneri, V, primary, Dieci, MV, additional, Bisagni, G, additional, Brandes, AA, additional, Frassoldati, A, additional, Cavanna, L, additional, Musolino, A, additional, Giotta, F, additional, Cavazzini, G, additional, Garrone, O, additional, Bertone, E, additional, Cagossi, K, additional, Nanni, O, additional, Ferro, A, additional, Donadio, M, additional, Aieta, M, additional, Zamagni, C, additional, Piacentini, F, additional, Maiorana, A, additional, Ragazzi, M, additional, Cucchi, MC, additional, Querzoli, P, additional, Orsi, N, additional, Curtarello, M, additional, Urso, L, additional, Amadori, A, additional, Orvieto, E, additional, Vicini, R, additional, Balduzzi, S, additional, D'Amico, R, additional, and Conte, P, additional

Published
2018
Full Text
View/download PDF

16. Primary chemotherapy in operable breast cancer with favorable prognostic factors: A pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN)

Author

Nolè, F., Minchella, I., Colleoni, M., Orvieto, E., Munzone, E., de Braud, F., Peruzzotti, G., Martinelli, G., Zampino, M.G., Catania, C., Pizzamiglio, M., Veronesi, P., Zurrida, S., Galimberti, V., Goldhirsch, A., and Veronesi, U.

Published
1999
Full Text
View/download PDF

18. A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in 739 patients (pts) affected by early stage pure Invasive Lobular breast Carcinoma (ILC)

Author

Carbognin, L., primary, Sperduti, I., additional, Arpino, G., additional, Dieci, M.V., additional, Schettini, F., additional, Guarneri, V., additional, Griguolo, G., additional, Nortilli, R., additional, Fiorio, E., additional, Parolin, V., additional, Pilotto, S., additional, Brunelli, M., additional, Manfrin, E., additional, Orvieto, E., additional, Pellini, F., additional, Pollini, G.P., additional, Conte, P., additional, De Placido, S., additional, Tortora, G., additional, and Bria, E., additional

Published
2017
Full Text
View/download PDF

19. First prospective multicenter Italian study on the impact of the 21-gene recurrence score (RS) in adjuvant clinical decisions for ER+/HER2- early breast cancer (BC) patients

Author

Dieci, M.V., primary, Guarneri, V., additional, Giarratano, T., additional, Mion, M., additional, Tortora, G., additional, Morandi, P., additional, Gori, S., additional, Merlini, L., additional, Oliani, C., additional, Pasini, F., additional, Bonciarelli, G., additional, Griguolo, G., additional, Orvieto, E., additional, Del Bianco, P., additional, De Salvo, G.L., additional, and Conte, P., additional

Published
2017
Full Text
View/download PDF

20. ESR1, Ph-mTOR, CDK4/6 and PD-L1 expression as prognostic (and potentially druggable) drivers for pure invasive lobular breast carcinoma (ILC): Preliminary results of prognostic outliers according to a clinical-pathological model

Author

Carbognin, L., primary, Brunelli, M., additional, Manfrin, E., additional, Caliò, A., additional, Sperduti, I., additional, Dieci, M.V., additional, Griguolo, G., additional, Guarneri, V., additional, Nortilli, R., additional, Pilotto, S., additional, Fiorio, E., additional, Parolin, V., additional, Orvieto, E., additional, Pellini, F., additional, Pollini, G.P., additional, Conte, P.F., additional, Scarpa, A., additional, Tortora, G., additional, and Bria, E., additional

Published
2017
Full Text
View/download PDF

21. Abstract P2-05-20: Tumor infiltrating lymphocytes in recurrent HER2+ and triple negative breast cancer: Prognostic value according to tumor phenotype

Author

Dieci, MV, primary, Giaratano, T, additional, Miglietta, F, additional, Griguolo, G, additional, Orvieto, E, additional, Falci, C, additional, Giorgi, CA, additional, Mioranza, E, additional, Tasca, G, additional, Cappellesso, R, additional, Ghiotto, C, additional, Conte, P, additional, and Guarneri, V, additional

Published
2017
Full Text
View/download PDF

24. First prospective multicenter Italian study on the impact of the 21-gene recurrence score® (RS) in adjuvant clinical decisions for ER + /HER2- early breast cancer patients

Author

Dieci, M.V., primary, Guarneri, V., additional, Mion, M., additional, Tortora, G., additional, Morandi, P., additional, Gori, S., additional, Merlini, L., additional, Oliani, C., additional, Pasini, F., additional, Bonciarelli, G., additional, Orvieto, E., additional, Del Bianco, P., additional, De Salvo, G.L., additional, and Conte, P.F., additional

Published
2016
Full Text
View/download PDF

25. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas

Author

Ferreri, Aj, Dell'Oro, S, Capello, D, Ponzoni, M, Iuzzolino, P, Rossi, D, Pasini, F, Ambrosetti, Achille, Orvieto, E, Ferrarese, F, Arrigoni, G, Foppoli, M, Reni, M, Gaidano, G., Ferreri, Ajm, Dell'Oro, S, Capello, D, Ponzoni, Maurilio, Iuzzolino, P, Rossi, D, Pasini, F, Ambrosetti, A, Orvieto, E, Ferrarese, F, Arrigoni, G, Foppoli, M, Reni, M, and Gaidano, G.

Subjects
Adult, Male, folate carrier, primary central nervous system lymphomas, Reverse Transcriptase Polymerase Chain Reaction, Membrane Transport Proteins, Antineoplastic Agents, Sequence Analysis, DNA, Middle Aged, Methylation, Central Nervous System Neoplasms, Reduced Folate Carrier Protein, Methotrexate, Drug Resistance, Neoplasm, Predictive Value of Tests, Prevalence, Humans, methotrexate, primary central nervous system lymphomas, folate carrier, CpG Islands, Female, Lymphoma, Large B-Cell, Diffuse, Aged
Abstract

We investigated the prevalence and prognostic role of CpG island methylation of the reduced folate carrier (RFC) gene promoter region in primary central nervous system lymphoma (PCNSL) in immunocompetent patients. Genomic DNA from 40 PCNSL was used for methylation-specific polymerase chain reaction and bisulphite genomic sequencing of the RFC promoter region. Human immunodeficiency virus-negative systemic diffuse large B-cell lymphomas (DLBCL) were used as controls (n = 50). The impact on outcome of RFC promoter methylation was assessed in 37 PCNSL patients treated with high-dose methotrexate (HD-MTX)-based chemotherapy +/- radiotherapy. RFC promoter methylation occurred in 12 of 40 (30%) PCNSL and in four of 50 (8%) DLBCL (P = 0.01). Of 37 PCNSL treated with HD-MTX-based chemotherapy, methylation occurred in nine cases (24%, M-PCNSL), while 28 cases (76%, U-PCNSL) were negative. Three M-PCNSL (33%) and 15 U-PCNSL (54%) achieved complete remission (CR) after primary chemotherapy. Logistic regression confirmed the independent association between CR rate and International Extranodal Lymphoma Study Group score (P = 0.03), RFC promoter methylation (P = 0.07) and use of cytarabine (P = 0.08). The 3-year failure-free survival (FFS) and overall survival for M-PCNSL and U-PCNSL was 0% vs. 31 +/- 9% (P = 0.34) and 0% vs. 31 +/- 9% (P = 0.35) respectively. This is the first study to assess the methylation status of the RFC promoter in human tumour samples. RFC methylation is more common in PCNSL compared with systemic DLBCL, and is associated with a lower CR rate to HD-MTX-based chemotherapy. If confirmed in prospective trials on PCNSL treated with HD-MTX alone, these data may suggest the necessity for alternative strategies in M-PCNSL considering the increased risk of MTX resistance by tumour cells.

Published
2004

26. 197P - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure invasive lobular breast carcinoma (ILC)

Author

Carbognin, L., Sperduti, I., Arpino, G., Dieci, M.V., Schettini, F., Griguolo, G., Brunelli, M., Guarneri, V., Nortilli, R., Fiorio, E., Pilotto, S., Orvieto, E., Manfrin, E., Conte, P., de Placido, S., Scambia, G., Tortora, G., and Bria, E.

Published
2018
Full Text
View/download PDF

27. 186O - Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial

Author

Dieci, M.V., Conte, P.F., Bisagni, G., Brandes, A.A., Frassoldati, A., Cavanna, L., Musolino, A., Giotta, F., Rimanti, A., Garrone, O., Bertone, E., Cagossi, K., Sarti, S., Ferro, A., Omarini, C., Maiorana, A., Orvieto, E., Sanders, M., D'Amico, R., and Guarneri, V.

Published
2018
Full Text
View/download PDF

28. Diffuse leptomeningeal glioneuronal tumours: clinico-pathological follow-up

Author

Gardiman, Marina, Matteo Fassan, Nozza, P., Orvieto, E., Garrè, Ml, Milanaccio, C., Severino, M., GIORGIO PERILONGO, and Giangaspero, F.

Subjects
Central Nervous System, Male, Adolescent, Meningeal Neoplasms, Humans, Neoplasms, Neuroepithelial
Abstract

Glioneuronal tumours are a group of primary brain neoplasms of relatively recent acquisition in the World Health Organization (WHO) Classification of the Central Nervous System tumours. In diagnostic practice it is still possible to encounter glioneuronal tumours that cannot be placed into any of the well-defined WHO categories despite a growing list of entities. We have recently published four paediatric cases of diffuse leptomeningeal tumours that cannot be easily classified in the currently used CNS WHO classification, but which have histological and immunohistochemical criteria to be considered as glioneuronal tumours. The clinical, neuroradiological and pathological long-term follow-up of an unusual diffuse leptomeningeal glioneuronal tumour is presented herein.

Published
2013

29. Prognostic scoring system for Primary Central Nervous System Lymphomas: the IELSG proposal

Author

Ferreri AJM, Blay J-Y, Calderoni A, Ambrosetti A, Tirelli U, Cortelazzo S, Gubkin A, Zucca E, Gomez H, Orvieto E, Borish B, Berger F, Jouvet A, Tingueli M, Chassagne C, Ponzoni M, Reni M, Ferreri, Ajm, Blay, J-Y, Calderoni, A, Ambrosetti, A, Tirelli, U, Cortelazzo, S, Gubkin, A, Zucca, E, Gomez, H, Orvieto, E, Borish, B, Berger, F, Jouvet, A, Tingueli, M, Chassagne, C, Ponzoni, M, and Reni, M

Published
2001

30. Pituitary tumor apoplexy presenting as infective meningoencephalitis

Author

Cagnin, Annachiara, Marcante, A, Orvieto, E, Manara, R., and Marcante, Andrea

Subjects
Adenoma, Male, medicine.medical_specialty, Pathology, Biopsy, Dermatology, Lesion, Diagnosis, Differential, Clivus, Meningoencephalitis, Medicine, Humans, Pituitary Neoplasms, Aged, 80 and over, medicine.diagnostic_test, business.industry, Pituitary tumors, Pituitary apoplexy, General Medicine, medicine.disease, Psychiatry and Mental health, medicine.anatomical_structure, Neurology (clinical), Neurosurgery, medicine.symptom, business, Meningitis, Pituitary Apoplexy
Abstract

We report on a case of a 80-year-old man who developed progressive drowsiness with headache, fever and signs of meningeal irritation 2 days after a head trauma. Suspecting an infective meningoencephalitis, the patient was treated with wide spectrum antibiotic and antiviral therapy. Brain CT scan revealed a previously unknown pituitary expansive lesion. A brain MRI study confirmed the presence of an intrasellar lesion, which presented remarkable contrast ring enhancement, and showed non-specific inflammatory tissue on the clivus, possibly responsible of the clinical features of sterile meningitis. A biopsy proven diagnosis of pituitary apoplexy was made. This case highlights MRI as an important investigation for earlier recognition of pituitary apoplexy that can present with a clinical picture resembling an infective meningoencephalitis.

Published
2012

31. Predictors of response and survival in primary central nervous system lymphoma (PCNSL): Analysis of an international multicentre series of 378 immunocompetent patients

Author

Ferreri, A. J. M., Jean-Yves Blay, Pasini, F., Spina, M., Vavassori, V., Ambrosetti, A., Calderoni, A., Rossi, A., Conconi, A., Devizzi, L., Berger, F., Ponzoni, M., Borisch, B., Tinguely, M., Cerati, M., Milani, M., Kaplanskaia, I., Orvieto, E., Sanchez, J., Chevreau, C., Camba, L., Villa, E., Cavalli, F., Ferreri, Ajm, Blay, Jy, Pasini, F, Spina, M, Vavassori, V, Ambrosetti, A, Calderoni, A, Rossi, A, Conconi, A, Devizzi, L, Berger, F, Ponzoni, Maurilio, Borisch, B, Tinguely, M, Cerati, M, Milani, M, Kaplanskaia, I, Orvieto, E, Sanchez, J, Chevreau, C, Camba, L, Villa, E, and Cavalli, F.

Published
2000

39. 204P - ESR1, Ph-mTOR, CDK4/6 and PD-L1 expression as prognostic (and potentially druggable) drivers for pure invasive lobular breast carcinoma (ILC): Preliminary results of prognostic outliers according to a clinical-pathological model

Author

Carbognin, L., Brunelli, M., Manfrin, E., Caliò, A., Sperduti, I., Dieci, M.V., Griguolo, G., Guarneri, V., Nortilli, R., Pilotto, S., Fiorio, E., Parolin, V., Orvieto, E., Pellini, F., Pollini, G.P., Conte, P.F., Scarpa, A., Tortora, G., and Bria, E.

Published
2017
Full Text
View/download PDF

50. Prediction of response to primary chemotherapy for operable breast cancer

Author

Colleoni, M, primary, Orvieto, E, additional, Nolé, F, additional, Orlando, L, additional, Minchella, I, additional, Viale, G, additional, Peruzzotti, G, additional, Robertson, C, additional, Noberasco, C, additional, Galimberti, V, additional, Sacchini, V, additional, Veronesi, P, additional, Zurrida, S, additional, Orecchia, R, additional, and Goldhirsch, A, additional

Published
1999
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results